/PRNewswire/ Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological.
New data indicates that there is a strong benefit-risk profile for upadacitinib for younger atopic dermatitis patients, with prior data predominantly relating to adult treatment.
Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share:
ResearchAndMarkets.com s offering.
This report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology as well as the CVU market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The CVU market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CVU market size from 2017 to 2030. The report also covers current CVU treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Scope of the Report